1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Delayed Nasdaq  -  04:00 2022-08-11 pm EDT
248.35 USD   -1.48%
08/11Senate Finance Committee looks at Amgen taxes, widening drugmaker probe
RE
08/11Senate finance committee chairman wyden sends amgen letter inqui…
RE
08/09Atlantic Equities Adjusts Amgen's Price Target to $182 from $190, Keeps Underweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen: FDA OK's Riabni Biosimilar to Rituxan in Rheumatoid Arthritis

06/06/2022 | 07:35am EDT

By Colin Kellaher


Amgen Inc. on Monday said the U.S. Food and Drug Administration approved the expanded use of its Riabni biosimilar to Rituxan in certain patients with the chronic inflammatory joint disease rheumatoid arthritis.

Amgen said the approval covers Riabni in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor antagonist therapies.

Biosimilars are near-copies of biologic drugs, such as Rituxan, that are made from living cells and are analogous to generic copies of traditional medicines.

Rituxan is jointly marketed by Biogen Inc. and Roche Holding AG's Genentech unit.

The FDA previously approved Riabni for the treatment of adults with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (also called Wegener's granulomatosis) and microscopic polyangiitis.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

06-06-22 0935ET

Stocks mentioned in the article
ChangeLast1st jan.
AMGEN INC. -1.48% 248.35 Delayed Quote.10.39%
BIOGEN INC. -1.28% 218.22 Delayed Quote.-9.04%
ROCHE HOLDING AG 1.72% 315.6 Delayed Quote.-18.19%
All news about AMGEN INC.
08/11Senate Finance Committee looks at Amgen taxes, widening drugmaker probe
RE
08/11Senate finance committee chairman wyden sends amgen letter inqui…
RE
08/09Atlantic Equities Adjusts Amgen's Price Target to $182 from $190, Keeps Underweight Rat..
MT
08/08AMGEN : Statement on Drug Pricing Provisions Included in “Inflation Reduction Act&rd..
PU
08/08Amgen Presents New Tarlatamab Clinical Data At WCLC 2022
CI
08/08TRANSCRIPT : Amgen Inc. - Special Call
CI
08/08TRANSCRIPT : Amgen Inc. Presents at International Association for the Study of Lung Cancer..
CI
08/08UBS Adjusts Amgen Price Target to $248 From $242, Maintains Neutral Rating
MT
08/08EFFECTOR Therapeutics Names Douglas Warner Chief Medical Officer
MT
08/07Amgen says Lumakras plus immunotherapy for lung cancer needs further study
RE
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2022 26 186 M - -
Net income 2022 6 252 M - -
Net Debt 2022 27 064 M - -
P/E ratio 2022 21,1x
Yield 2022 3,12%
Capitalization 133 B 133 B -
EV / Sales 2022 6,11x
EV / Sales 2023 5,80x
Nbr of Employees 24 200
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 248,35 $
Average target price 250,10 $
Spread / Average Target 0,71%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.10.39%132 850
JOHNSON & JOHNSON-2.30%439 441
ELI LILLY AND COMPANY9.03%286 164
ROCHE HOLDING AG-16.39%272 759
PFIZER, INC.-18.22%271 020
ABBVIE INC.4.93%251 211